The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer.
Nishith K. Singh
No relevant relationships to disclose
Joseph W. Kim
No relevant relationships to disclose
Christopher Ryan Heery
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose
Anna Couvillon
No relevant relationships to disclose
Myrna Rauckhorst
No relevant relationships to disclose
Sheri McMahon
No relevant relationships to disclose
Jeffrey Schlom
No relevant relationships to disclose
Tito Fojo
No relevant relationships to disclose
Philip M. Arlen
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose